Clayton Financial Group’s AbbVie ABBV Stock Holding History

Clayton Financial Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.45M	Sell	5,762 -1,204	-17%	-$259K	0.8%	19
2026 Q1	$1.52M	Hold	6,966	–	–	0.78%	20
2025 Q4	$1.59M	Buy	6,966 +794	+13%	+$181K	0.81%	20
2025 Q3	$1.43M	Buy	+6,172	New	+$1.26M	1.04%	15
2025 Q2	–	Sell	-3,628	Closed	-$760K	–	30
2025 Q1	$760K	Hold	3,628	–	–	0.28%	53
2024 Q4	$645K	Hold	3,628	–	–	0.23%	61
2024 Q3	$716K	Buy	3,628 +1,723	+90%	+$322K	0.27%	55
2024 Q2	$347K	Hold	1,905	–	–	0.15%	71
2024 Q1	$347K	Buy	+1,905	New	+$328K	0.16%	70

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Clayton Financial Group's ABBV Position: Q2 2026 in Review

Clayton Financial Group reduced its AbbVie (ABBV) stake by 17% in Q2 2026, selling an estimated $259K and leaving 5,762 shares worth $1.45M. The position accounts for 0.8% of the portfolio, ranked #19.

Clayton Financial Group first reported a position in ABBV in Q1 2024 and has held it in 9 quarters since. The position peaked at $1.59M in Q4 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Clayton Financial Group held 5,762 shares of AbbVie worth $1.45M as of Q2 2026.
Clayton Financial Group sold 1,204 AbbVie shares in Q2 2026, an estimated $259K.
AbbVie made up 0.8% of Clayton Financial Group's portfolio in Q2 2026, its #19 holding.
Clayton Financial Group first reported a position in AbbVie in Q1 2024 and has held it in 9 quarters since.
Clayton Financial Group's AbbVie position peaked at $1.59M in Q4 2025.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Clayton Financial Group's 13F filing for Q2 2026, filed 20 Jul 2026.